Ypsomed Holding AG
SIX:YPSN

Watchlist Manager
Ypsomed Holding AG Logo
Ypsomed Holding AG
SIX:YPSN
Watchlist
Price: 321 CHF -0.16% Market Closed
Market Cap: 4.4B CHF

Ypsomed Holding AG
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ypsomed Holding AG
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Ypsomed Holding AG
SIX:YPSN
Net Income (Common)
CHf87.5m
CAGR 3-Years
56%
CAGR 5-Years
49%
CAGR 10-Years
16%
Alcon AG
SIX:ALC
Net Income (Common)
$1.1B
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Coltene Holding AG
SIX:CLTN
Net Income (Common)
CHf14.3m
CAGR 3-Years
-18%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Medartis Holding AG
SIX:MED
Net Income (Common)
-CHf487k
CAGR 3-Years
-26%
CAGR 5-Years
35%
CAGR 10-Years
N/A
IVF Hartmann Holding AG
SIX:VBSN
Net Income (Common)
CHf19m
CAGR 3-Years
37%
CAGR 5-Years
6%
CAGR 10-Years
2%
No Stocks Found

Ypsomed Holding AG
Glance View

Market Cap
4.4B CHF
Industry
Health Care

Nestled amid the pioneering spirit of the Swiss medical technology landscape, Ypsomed Holding AG emerges as a quintessential player, carving a niche in the diabetes care and injection systems domains. The company’s journey begins in the Ypsomed headquarters in Burgdorf, Switzerland, where innovation meets precision engineering. Ypsomed's focus largely revolves around its development, production, and distribution of self-injection devices and solutions. This Swiss dynamo engages in crafting state-of-the-art insulin pumps, pen injectors, and smart add-on devices that empower users with diabetes to manage their conditions effectively. It combines clinical expertise with intuitive design, ensuring that their diverse clientele—from patients to medical professionals—receive products that blend seamlessly into everyday life. Not resting on insulin delivery alone, Ypsomed also establishes itself in the world of contract manufacturing, catering to global pharmaceutical and biotech companies with their platform technology and customized solutions. Economically vibrant, Ypsomed’s revenue streams are woven intricately from an array of channels. A significant proportion stems from direct sales of its proprietary diabetes care products under their acclaimed mylife™ brand. Here, it garners a loyal customer base through innovations like the YpsoPump® system, effectively capitalizing on the growing demand for user-friendly diabetes management tools. Additionally, Ypsomed capitalizes on partnerships with major healthcare multinationals by providing contract manufacturing services and licensing technologies, expanding its global footprint while tapping into broader markets. As a strategic player, the company continuously invests in research and development to refine its offerings and maintain a competitive edge in the burgeoning medical device market. Through this dynamic blend of cutting-edge technology and strategic alliances, Ypsomed illustrates a sophisticated business model that not only sustains its profitability but furthers its mission to improve the lives of those in need of reliable, advanced diabetes care solutions.

YPSN Intrinsic Value
HIDDEN
Show

See Also

What is Ypsomed Holding AG's Net Income (Common)?
Net Income (Common)
87.5m CHF

Based on the financial report for Mar 31, 2025, Ypsomed Holding AG's Net Income (Common) amounts to 87.5m CHF.

What is Ypsomed Holding AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
16%

Over the last year, the Net Income (Common) growth was 12%. The average annual Net Income (Common) growth rates for Ypsomed Holding AG have been 56% over the past three years , 49% over the past five years , and 16% over the past ten years .

Back to Top